Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03997786 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03997786 · ClinicalTrials.gov record · last posted 2026-04-15

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

StatusActive, Not Recruiting
PhasePhase 2/3
Started2020-01-15
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE). The initial PK analysis is first done in adolescent subjects (12 to \<18 years) before initiating the PK study in younger cohort (6 to \<12 years)

Amendment record 23 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 23 times since 2019-06-24; most recent amendment 2026-04-06. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-03-18
Status change Recruiting→Active, Not Recruitingv22
2025-02-25
Status change Active, Not Recruiting→Recruitingv21
2024-06-19
Status change Recruiting→Active, Not Recruitingv19
2020-02-11
Status change Not Yet Recruiting→Recruitingv5
Trial Details
NCT Number NCT03997786
Lead Sponsor Sun Pharmaceutical Industries Limited
Conditions Moderate-to-severe Chronic Plaque Psoriasis
Enrollment 135 participants
Start Date 2020-01-15
Primary Completion 2025-04-07 (estimated)
Study Completion 2031-08-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-15